InBody Co.,Ltd

KOSDAQ 041830.KQ

InBody Co.,Ltd Net Income for the year ending December 31, 2023: USD 28.20 M

InBody Co.,Ltd Net Income is USD 28.20 M for the year ending December 31, 2023, a 5.57% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

InBody Co.,Ltd Net Income for the year ending December 31, 2022 was USD 26.71 M, a -6.22% change year over year.
InBody Co.,Ltd Net Income for the year ending December 31, 2021 was USD 28.49 M, a 77.14% change year over year.
InBody Co.,Ltd Net Income for the year ending December 31, 2020 was USD 16.08 M, a -8.68% change year over year.
InBody Co.,Ltd Net Income for the year ending December 31, 2019 was USD 17.61 M, a 0.14% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

KOSDAQ: 041830.KQ

InBody Co.,Ltd

CEO	Dr. Ki-Chul Cha
IPO Date	Dec. 15, 2000
Location	South Korea
Headquarters	InBody Building
Employees	266
Sector	Health Care
Industries Medical Instruments Cosmetics Pharmaceuticals

Description

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years